No Data
Eddy Pharmaceuticals 2024 Annual Results Express Announcement
Jiangsu Aidea Pharmaceutical (688488.SH): Net loss of 0.13 billion yuan for the year 2024.
Gelonghui February 27丨Jiangsu Aidea Pharmaceutical (688488.SH) announced the performance report for 2024. During the reporting period, the company's total operating revenue was 419.265 million yuan, an increase of 1.92% compared to the same period last year; the operating profit was -151.8265 million yuan, which is a decrease of 64.94% compared to the same period last year; the total profit was -153.0564 million yuan, which represents a decrease of 66.21% compared to the same period last year; the net income attributable to the owners of the parent company was -129.9185 million yuan, a decrease of 70.79% compared to the same period last year; the net income attributable to the owners of the parent company after deductions.
Eddy Pharmaceuticals 2024 Annual Results Forecast
Jiangsu Aidea Pharmaceutical (688488.SH): Elected Fu Heling as Director.
Gelonghui, January 3rd丨Jiangsu Aidea Pharmaceutical (688488.SH) announced that on January 3, 2025, the company will hold the first meeting of the third Board of Directors, where all directors unanimously agreed to elect Mr. Fu Helian as the chairman of the third Board of Directors.
Jiangsu Aidea Pharmaceutical (688488.SH): New core technical personnel identified as Qin Hong, Li Qide, and Sun Tie.
Jiangsu Aidea Pharmaceutical (688488.SH) issued a notice that the company's senior management and core technical personnel Hong ...
Insiders With Their Considerable Ownership Were the Key Benefactors as Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) Touches CN¥4.1b Market Cap
What Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) 27% Share Price Gain Is Not Telling You